Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Daley

Showing results (131-140 of 230) with videos related to

Pageof 23
Sort By:
Diagnostic Microbiology and Infectious Disease|December 25, 2018
Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolatesSu-Young Kim, Byung Woo Jhun, Seong Mi Moon, et al.
The European Respiratory Journal|January 24, 2015
The tolerability of linezolid in the treatment of nontuberculous mycobacterial diseaseKevin L Winthrop, Jennifer H Ku, Theodore K Marras, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2017
Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung DiseaseBumhee Yang, Byung Woo Jhun, Seong Mi Moon, et al.
American Journal of Respiratory and Critical Care Medicine|May 6, 2006
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosisWilliam J Burman, Stefan Goldberg, John L Johnson, et al.
The European Respiratory Journal|October 18, 2019
Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up studyByung Woo Jhun, Seong Mi Moon, Kyeongman Jeon, et al.
Antimicrobial Agents and Chemotherapy|August 15, 2018
Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus ComplexSun Hye Shin, Byung Woo Jhun, Su-Young Kim, et al.
Antimicrobial Agents and Chemotherapy|July 26, 2017
Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung DiseaseHayoung Choi, Su-Young Kim, Dae Hun Kim, et al.
Respiratory Investigation|January 10, 2026
Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trialKozo Morimoto, James D Chalmers, Pierre-Régis Burgel, et al.
The Pediatric Infectious Disease Journal|December 15, 2015
Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall IslandsSundari R Mase, John A Jereb, Daniel Gonzalez, et al.
The New England Journal of Medicine|September 8, 2020
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in BronchiectasisJames D Chalmers, Charles S Haworth, Mark L Metersky, et al.
Pageof 23

Showing results (131-140 of 230) with videos related to

Sort By:
Pageof 23
Diagnostic Microbiology and Infectious Disease|December 25, 2018
Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolatesSu-Young Kim, Byung Woo Jhun, Seong Mi Moon, et al.
The European Respiratory Journal|January 24, 2015
The tolerability of linezolid in the treatment of nontuberculous mycobacterial diseaseKevin L Winthrop, Jennifer H Ku, Theodore K Marras, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2017
Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung DiseaseBumhee Yang, Byung Woo Jhun, Seong Mi Moon, et al.
American Journal of Respiratory and Critical Care Medicine|May 6, 2006
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosisWilliam J Burman, Stefan Goldberg, John L Johnson, et al.
The European Respiratory Journal|October 18, 2019
Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up studyByung Woo Jhun, Seong Mi Moon, Kyeongman Jeon, et al.
Antimicrobial Agents and Chemotherapy|August 15, 2018
Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus ComplexSun Hye Shin, Byung Woo Jhun, Su-Young Kim, et al.
Antimicrobial Agents and Chemotherapy|July 26, 2017
Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung DiseaseHayoung Choi, Su-Young Kim, Dae Hun Kim, et al.
Respiratory Investigation|January 10, 2026
Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trialKozo Morimoto, James D Chalmers, Pierre-Régis Burgel, et al.
The Pediatric Infectious Disease Journal|December 15, 2015
Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall IslandsSundari R Mase, John A Jereb, Daniel Gonzalez, et al.
The New England Journal of Medicine|September 8, 2020
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in BronchiectasisJames D Chalmers, Charles S Haworth, Mark L Metersky, et al.
Pageof 23